Case Study

Clinical Bioequivalence Study for an NDA-Track Generic

Confidential Generic Developer Pharmaceuticals

Sponsor needed a GCP/GLP bioequivalence study on a complex oral dosage form with TK endpoints and USFDA submission quality.

Combined clinical + bioanalytical teams under one study director. In-house LC-MS/MS method transfer cut sample analysis time by 30%.